small interfering RNA targeting CD320 + small interfering RNA targeting LRP2

**small interfering RNA targeting CD320 + small interfering RNA targeting LRP2** is an investigational dual-target RNA interference cancer therapeutic being developed by bioAffinity Technologies. The product consists of a combination of small interfering RNAs designed to silence expression of the cell-surface receptors CD320 and LRP2 in tumor cells. Preclinical in vitro studies reported by the company show that concurrent knockdown of both targets selectively inhibits proliferation or induces death of cancer cell lines derived from lung, breast, prostate, brain, and skin tumors while sparing normal cells; the dual-target approach appears important because single-target silencing can trigger compensatory upregulation of the other receptor. The program is positioned as a targeted antineoplastic RNA therapy, with ongoing preclinical work exploring a topical formulation for cutaneous malignancies and other skin neoplasms. No proprietary brand name or formal development code appears to have been publicly disclosed.

Other names

small interfering RNA targeting CD320 + small interfering RNA targeting LRP2targeting CD320/LRP2 siRNA therapysiRNA targeting CD320 + siRNA targeting LRP2dual-target CD320/LRP2 siRNA therapy